• Directory
  • Search
  • All results
  • Journals
  • Definitions
Immunologic Factor
oprelvekin Audio
[ oh-prel-veh-kin ]
Brand Names:
Neumega
Effect:
Increased Megakaryocte Cell Production; Increased Thromboxane Production
May Prevent:
Thrombocytopenia
Definitions related to oprelvekin:
  • A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Neumega is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. It is a type of biological response modifier.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
  • A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
Return to MedicalPhysicist Medical Dictionary > O
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.

  • About
  • Feedback
  • Guides
  • Terms
© 2022 www.medicalphysicist.co.uk
The content on this site is NOT a substitute for professional medical advice or diagnosis. Always seek the advice of your doctor or health care provider.